High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1111-1116

  Rasouli Nia, Aghdass ^a   Liu, Dan ^a   Perdue, Sherry ^a   Britten, Richard A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN KINASE; RAF PROTEIN;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; NEOPLASM PROTEINS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-RAF; TRANSFECTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0031949369     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Burkhart, C. A., Berman, J. W., Swindell, C. S., and Horwitz, S. B. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor a gene expression and cytotoxicity. Cancer Res., 54: 5779-5782, 1994.
2. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
3. Kumar, N. Taxol-induced polyemrization of purified tubulin. Mechanism of action. J. Biol. Chem., 256: 10435-10441, 1981.
4. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res., 48: 4093-4100, 1988.
5. Roberts, J. R., Allison, D. C., Donehower, R. C., and Rowinsky, E. K. Development of polyploidization in Taxol-resistant human leukemia cells in vitro. Cancer Res., 50: 710-716, 1990.
6. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
7. Bhalla, K., Ibrado, A. M., Tourkina, E., Tang, C., Mahoney, M. E., and Huang, Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia (Baltimore), 7: 563-568, 1993.
8. cdc coincident with Taxol-induced apoptosis. Cell Growth Differ., 5: 1041-1050, 1994.
9. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in Taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
10. Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transducuon pathway. Cancer Res., 56: 1851-1854, 1996.
11. v-srcl. Cancer Res., 49: 780-785, 1989.
12. June, C. H., Fletcher, M. C., Ledbetter, J. A., Schieven, G. L., Siegel, J. N., Phillips, A. F., and Samelson, L. E. Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 87: 7722-7726, 1990.
13. v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
14. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11: 933-939, 1995.
15. Rosell, R., González-Larriba, J. L., Alberola, V., Molina, F., Monzó, M., Benito, D., Pérez, J. M., and de Anta, J. M. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin. Oncol., 22: 12-18, 1995.
16. WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
17. Wang, H-G., Rapp, U. R., and Reed, J. C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 87: 629-638, 1996.
18. Haldar, S., Jena, N., and Croce, C. M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
19. Britten, R. A., Evans, A. J., Allalunis-Turner, M. J., and Pearcey, R. G. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int. J. Radiat. Oncol. Biol. Phys., 34: 367-374, 1996.
20. Britten, R. A., Evans, A. J., Allalunis-Turner, M. J., Franko, A. J., and Pearcey, R. G. Intratumoral heterogeneity as a confounding factor in clonogenic assays for tumor radioresponsiveness. Radiother. Oncol., 39: 145-153, 1996.
21. Allalunis-Turner, M. J., Pearcey, R. G., Barron, G. M., Buryn, D. A., Babiak, J. C., and Honoré, L. H. Inherent radiosensitivity testing of tumor biopsies obtained from patients with carcinoma of the cervix or endometrium. Radiother. Oncol., 22: 201-205, 1991.
22. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmaco-dynamics of paclitaxel, a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res., 1: 599-606, 1995.
23. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Locatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolisms of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol., 13: 180-190, 1995.
24. Patel, B. K. R., and Kasid, U. Nucleotide sequence analysis of c-raf-1 cDNA and promoter from a radiation-resisiant human squamous carcinoma cell line: deletion within exon 17. Mol. Carcinog., 8: 7-12, 1993.
25. Mcllwrath, A. J., Brunton, V. G., and Brown, R. Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemother. Pharmacol., 37: 423-428, 1996.
26. Bhalla, K., Ibrado, A. M., Brandt, J. E., Ray, S., Huang, Y., Tang, C., Nawabi, A., and Hoffman, R. pIXY321 protects against Ara-C or Taxol-induced apoptosis and loss of clonogenic survival of normal human bone marrow progenitor cells. Leukemia (Baltimore), 9: 1851-1856, 1995.
27. Maldonado, V., DeAnda, J., and Melendez-Zajgla, J. Paclitaxel-induced apoptosis in HeLa cells is serum dependent. J. Biochem. Toxicol., 11: 183-186, 1996.
28. Fennelly, D. W., Aghajanian, C., Shapiro, F., O'Flaherty, C., O'Connor, K., Curtin, J. P., Crown, J. P., Hoskins, W. J., and Spriggs, D. R. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin. Oncol., 24: S2-26-S2-30, 1997.
29. 2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
30. Pim, D., Massimi, P., and Banks, L. Alternatively spliced HPV-18E6* protein inhibits E6-mediated degradation of p53 and suppresses transformed cell growth. Oncogene, 15: 257-264, 1997.
31. Gibb, R. K., Taylor, D. D., Wan, T., O'Connor, D. M., Doering, D. L., and Gerçel-Taylor, C. Apoptosis as a measure of chemosensitivity to cisplatin and Taxol therapy in ovarian cancer cell lines. Gynecol. Oncol., 65: 13-22, 1997.
32. Menendez, A. T., Laidlaw, J., Raventos-Suarez, C., Gelbert, L., Granas, A., Li, M-X., and Kramer, R. Taxol induces apoptosis by a p53/p21-independent mechanism in cisplatin-resistant ovarian carcinoma cells. Proc. Am. Assoc. Cancer Res., 38: A628, 1997.